PTGS2 and Hypertension: A later meta-analysis of 51 trials, considering all three component parts of the MEDAL program, confirmed the heterogeneity of the effect of different COX-2 selective inhibitors (celecoxib, rofecoxib, etoricoxib, valdecoxib, and lumiracoxib) on BP and hypertension [69], with etoricoxib (risk ratio [95% Cl], 1.52 [1.39–1.66], p < 0.01), but not celecoxib (0.89 [0.77–1.01], p = 0.22), being associated with increased risk of SBP elevation [69].